Five-year remission rates with cilta-cel in earlier-line relapsed or refractory multiple myeloma
The analysis, led by Adam D. Cohen, MD, of University of Pennsylvania in Philadelphia, reviewed 20 patients from Cohort A of the CARTITUDE-2
Multiple Myeloma
Trending now
Leukemia
Acute Lymphoblastic Leukemia
Blinatumomab effectively replaces conventional chemotherapy cycles for pediatric patients with B-ALL
The study’s authors, led by Marin Schrappe, MD, of Christian Albrechts University Kiel and University Hospital Schleswig-Holstein in Germany, enrolled pediatric patients with
Trending now
Leukemia
Acute Lymphoblastic Leukemia
News
Frontline blinatumomab plus chemotherapy offers promising MRD, relapse, survival outcomes for Ph–negative B-ALL
“This chemotherapy-blinatumomab risk-oriented program yielded remarkable results that need further improvement in higher-risk patients displaying early MRD persistence,” wrote the study’s authors, led
Trending now
Multiple Myeloma
Iberdomide combination improves MRD–negative complete response rates versus DVd in relapsed or refractory multiple myeloma
The combination of iberdomide, a novel cereblon E3 ligase modulator, with daratumumab and dexamethasone improved rates of minimal residual disease–negative complete response compared
Leukemia
Acute Lymphoblastic Leukemia
Incorporating blinatumomab into frontline therapy for high-risk B-ALL improves MRD, survival outcomes
The authors, led by Nicolas Boissel, MD, PhD, of Hôpital Saint-Louis in Paris, France, analyzed 94 patients with high-risk B-ALL who received up
Meetings / Conferences
SOHO 2026
Acute Lymphoblastic Leukemia News
News
Dose-dense mini-CVD plus inotuzumab ozogamicin, blinatumomab demonstrates deep, durable responses in relapsed or refractory B-ALL
The analysis, led by Hannah Goulart, MD, of The University of Texas MD Anderson Cancer Center in Houston Texas, was presented at the
Leukemia
Acute Lymphoblastic Leukemia
Phase 1b trial reports promising outcomes with olverembatinib plus blinatumomab in relapsed or refractory CML or ALL
The study, led by Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center in Houston, was presented at the Fourteenth
SOHO 2026
Acute Lymphoblastic Leukemia News
Obe-cel provides consistent efficacy and safety for relapsed or refractory B-ALL regardless of EMD status
ae H Park, MD, of Memorial Sloan Kettering Cancer Center in New York, and colleagues presented the findings at the Fourteenth Annual Meeting
Meetings / Conferences
SOHO 2026
Multiple Myeloma News
Oral cryotherapy reduces mucositis after high-dose melphalan before ASCT
Amifostine and uproleselan also showed “meaningful promise” for reducing mucositis and delaying severe diarrhea and improving GI quality of life, respectively, but require
Meetings / Conferences
SOHO 2026
Multiple Myeloma News
Anselamimab offers significant reduction in all-cause mortality and cardiovascular hospitalization risk for kappa AL amyloidosis
The study, led by Ashutosh Wechalekar, MD, of National Amyloidosis Centre and University College London Hospitals in the United Kingdom, analyzed a combined